HYPORT辅助试验急性毒性和患者剂量学质量保证结果——中期分析
HYPORT辅助试验是一项随机III期开放标签非劣效性试验,比较乳腺癌标准3周中度大分割辅助放疗与新型1周方案。报告前271例患者的剂量学质量保证、急性毒性及预设首次中期安全性分析结果:除1例因内乳淋巴结覆盖导致对侧乳腺剂量偏高外,所有强制性剂量学标准均达标;3例(1.1%)发生3级放射性皮炎(均未接受SIB),未报告其他3级及以上毒性。结论认为大分割辅助放疗联合SIB可行且严重急性毒性轻微。
要点
- 前271例患者中,除1例对侧乳腺剂量偏高外,所有强制性剂量学标准均达标。
- 3例(1.1%)发生3级放射性皮炎,均未接受SIB,未报告其他3级及以上毒性。
- 结论认为大分割辅助放疗联合SIB可行,严重急性毒性轻微。
核心结论
- 该急性毒性中期分析表明,对乳腺癌患者行大分割辅助放疗联合SIB是可行的,且严重急性毒性轻微。
研究设计与样本
- HYPORT辅助试验为随机III期开放标签非劣效性试验,2019年3月启动,总样本量2100例,正在招募中。
- 本次报告前271例患者的剂量学质量保证、急性毒性及预设首次中期安全性分析结果。
- I-III期乳腺癌患者随机接受40 Gy/15次/3周或26 Gy/5次/1周辅助放疗(乳腺/胸壁,必要时区域淋巴结)。
主要发现
- 前271例患者中104例接受SIB瘤床补量。
- 除1例因内乳淋巴结覆盖优化导致对侧乳腺剂量偏高外,所有强制性剂量学标准均达标。
- 3例(1.1%)发生3级放射性皮炎(均未接受SIB),未报告其他3级及以上毒性。
关键数值与推荐
- 对照组:40 Gy/15次/3周;试验组:26 Gy/5次/1周。
- SIB补量:对照组8 Gy/15次/3周至瘤床,试验组6 Gy/5次/1周至瘤床。
- 序贯补量:两组均为12 Gy/4次/4天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HYPORT adjuvant trial is a randomised phase III open-label noninferiority trial comparing standard moderately hypofractionated 3 week adjuvant radiation therapy in breast cancer with a novel 1-week schedule. The trial was initiated in March 2019 and is open to recruitment with a total sample size of 2100. We report the results of dosimetric quality assurance, acute toxicity and pre planned first interim safety analysis in the first 271 patients. METHODS: Stage I-III breast cancer planned for adjuvant radiation therapy to the breast/chest-wall (along with regional nodes as indicated) were randomised to receive 40 Gy/15 fractions/3 weeks or 26 Gy/5 fractions/1 week. For simultaneous integrated boost, the patients in the control arm received 8 Gy/15 fractions/3 weeks, while those in the experimental arm received 6 Gy/5 fractions/1 week (to the tumour bed). For sequential boost, the prescribed dose was 12 Gy/4 fractions/4 days in both arms. Compliance to pre specified dosimetric parameters and acute toxicities were evaluated. RESULT: Data of the first 271 patients was analysed of whom 104 patients received tumour bed boost using SIB. All mandatory dosimetric criteria were met apart from one patient with a higher contralateral breast dose due to optimal internal mammary nodal coverage. Overall three patients (1.1%) experienced grade 3 radiation dermatitis (none received SIB), no other Grade 3 or higher toxicities reported. CONCLUSION: This acute toxicity interim analysis demonstrates that hypofractionated adjuvant radiotherapy with SIB for patients with breast cancer is feasible, and associated with minimal severe acute toxicities.
引用
- Chakraborty S, Chatterjee S. HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results - Interim analysis. Radiother Oncol. 2022. PMID: 35817323. doi:10.1016/j.radonc.2022.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。